血清BNP、LCN-2在慢性心力衰竭患者疾病严重程度及预后评价的临床价值

摘要/Abstract

摘要： 目的探讨血清BNP、LCN-2检测在慢性心衰患者疾病严重程度及预后评价的临床价值。方法本次研究心衰的患者选取2019年1月至2023年6月在该院实施的90例作为研究组;同时选取同一时期在该院体检且结果显示心脏健康者作为对照组,共纳入90例,对比两组血清BNP、LCN-2检测水平,分析其对急慢性心衰患者严重程度及预后判断的临床价值。结果观察组LCN-2（89.678±17.48）ng/mL、BNP（2568.11±478.28）pg/mL均高于对照组（60.04±15.31）ng/mL、（196.41±47.49）pg/mL,差异有统计学意义（t=9.782、24.543,P<0.05）;观察组随心功能分级升高,BNP及LCN-2水平同步升高,差异有统计学意义（F=19.261、602.689,P<0.05）;观察组未发生心血管不良事件76例,发生心血管不良事件14例,发生心血管不良事件患者的BNP及LCN-2水平均显著高于未发生心血管不良事件患者,差异有统计学意义（t=2.218、2.221,P<0.05）。结论 BNP及LCN-2水平变化对于评价慢性心衰患者疾病严重程度及预后有可靠的临床价值,值得推广并应用。

关键词: BNP, LCN-2, 慢性心衰, 心衰程度, 预后

Abstract: Objective To investigate the clinical value of serum BNP and LCN-2 in evaluating the disease severity and prognosis of patients with chronic heart failure. Methods A total of 90 patients with heart failure who were treated in our hospital from January 2019 to June 2023 were enrolled as observation group, and 90 individuals who underwent cardiac examination in our hospital during the same period of time and had normal results were enrolled as control group. The two groups were compared in terms of the serum levels of BNP and LCN-2, and their clinical value in evaluating the disease severity and prognosis of patients with chronic heart failure was analyzed. Results Compared with the control group, the observation group had significantly higher levels of LCN-2 (89.678±17.48 ng/mL vs 60.04±15.31 ng/mL, t=9.782, P<0.05) and BNP (2568.11±478.28 pg/mL vs 196.41±47.49 pg/mL, t=24.543, P<0.05). In the observation group, the levels of BNP and LCN-2 increased with the increase in cardiac functional grade (F=19.261 and 602.689, P<0.05). In the observation group, there were 14 patients with major adverse cardiovascular events and 76 without such events, and the patients with major adverse cardiovascular events had significantly higher levels of BNP and LCN-2 than those without such events (t=2.218 and 2.221, P<0.05). Conclusion Changes in the levels of BNP and LCN-2 have a reliable clinical value in evaluating the disease severity and prognosis of patients with chronic heart failure and thus holds promise for clinical application.

Key words: BNP, LCN-2, Chronic heart failure, Severity of heart failure, Prognosis

陈利广, 沈雪彬. 血清BNP、LCN-2在慢性心力衰竭患者疾病严重程度及预后评价的临床价值[J]. 心血管病防治知识, 2023, 13(28): 18-21.

CHEN Li-guang, SHEN Xue-bin. Clinical value of serum BNP and LCN-2 in evaluating disease severity and prognosis of patients with chronic heart failure[J]. Prevention and Treatment of Cardiovascular Disease, 2023, 13(28): 18-21.

参考文献

[1] Wang XY, Zhang F, Zhang C, et al.The Biomarkers for Acute Myocardial Infarction and Heart Failure[J]. Biomed Res Int, 2020,20202018035.
[2] 中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会,血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.
[3] 郭丽,王露露,张丽,等.关于心力衰竭标志物研究的进展.心血管康复医学杂志,2019,28(2):251-256.
[4] 魏安华,李娟.《中国心力衰竭诊断和治疗指南 2018》药物更新透视.医药导报,2019,38(5):539-543.
[5] 戴书连,诸波,高发林,等.心力衰竭患者血清D-D、Cys-C、 NT-proBNP、hs-cTnI和CRP水平及其对预后评估的价值[J].临床和实验医学杂志,2021,20(11):1152-1155.
[6] Islam MN, Chowdhury MS, Paul GK, et al.Association of diastolic dysfunction with N-terminal pro-b-type natriuretic peptide level in heart failure patients with preserved ejection fraction[J].Mymensingh Med J,2019, 28( 2 ): 333-346.
[7] 储莉,刘伏元,闻伟,等.CK-MB、cTnI联合Fib对老年慢性心力衰竭患者诊断和预后的价值[J].中国老年学杂志,2021,41(14):2927-2931.
[8] 曾伟,高辰玮,李学永.三维斑点追踪技术预测急性心肌梗死患者近期急性心衰风险的研究[J].中国医学装备,2021,18(4):92-96.
[9] 陈金焕,张义林.急性心力衰竭患者血浆N末端B型利钠肽前体、超敏C反应蛋白、肌钙蛋白Ⅰ 和糖类抗原1 25与心功能的相关性分析[J].中国基层医药,2020,27(7):808-812.
[10] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.慢性心力衰竭基层诊疗指南(2019年)[J].中华全科医师杂志,2019,18(10):936-947.
[11] Díez-Villanueva P, Vera A, Ariza-Solé A,et al.Baseline CHA(2) DS(2)-VASc score and prognosis in octogenarians with non-ST segment elevation acute coronary syndrome[J]. Int J Clin Pract, 2021, 75(6): e14082.
[12] 周海娟,陈刚.温阳补心联合康复锻炼对心阳虚症慢性心力衰竭患者 NT-proBNP 及心功能的影响.辽宁中医杂志,2019,46(2):311-314
[13] Dillinger JG, Ducrocq G, Elbez Y, et al.Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial[J]. Circ Cardiovasc Interv, 2021, 14(1): e009759.
[14] Stojkovic S, Wadowski PP, Haider P, et al.Circulating MicroRNAs and Monocyte-Platelet Aggregate Formation in Acute Coronary Syndrome[J].Thromb Haemost, 2021, 121(7): 913-22.
[15] Chandiramani R, Cao D, Mehran R.Periprocedural anticoagulation innon-ST-segment elevation acute coronary syndrome: time to reassess[J]. Ann Transl Med, 2020, 8(8): 556.
[16] 王淑婵,冯书锐. UMA、BNP、 hsCRP 及 UACR 联合检测对慢性心衰患者的诊治及预后评估的价值.海南医学,2019,27(15):2432-2434.
[17] 李牧文. 重组人脑利钠肽和硝普钠对急性心力衰竭患者心功能及NT-proBNP、 cTnI、 hs-CRP的调节[J].吉林医学,2021,42(7):1666-1668.
[18] 李牧文. 重组人脑利钠肽和硝普钠对急性心力衰竭患者心功能及NT-proBNP、cTnI、BNP的调节[J].吉林医学,2021,42(7):1666-1668.
[19] 黄翡. 老年慢性心力衰竭患者血浆N端脑钠肽前体的变化及意义[J].智慧健康,2020,6(5):5-6